Belpointe Asset Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Belpointe Asset Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6	Closed	-$213	–	1656
2023 Q1	$213	Hold	6	–	–	﹤0.01%	3668
2022 Q4	$244	Buy	+6	New	+$252	﹤0.01%	3615
2018 Q4	–	Sell	-4,480	Closed	-$504K	–	550
2018 Q3	$504K	Buy	4,480 +14	+0.3%	+$1.48K	0.08%	261
2018 Q2	$412K	Sell	4,466 -338	-7%	-$32.8K	0.12%	206
2018 Q1	$479K	Buy	4,804 +2,153	+81%	+$232K	0.14%	174
2017 Q4	$249K	Sell	2,651 -111	-4%	-$10.5K	0.05%	376
2017 Q3	$281K	Buy	+2,762	New	+$241K	0.07%	328

Other funds holding LKFT

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

Belpointe Asset Management's LKFT Position: Q2 2023 in Review

Belpointe Asset Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2023, closing a stake of 6 shares — an estimated $213 sold.

Belpointe Asset Management first reported a position in LKFT in Q3 2017 and held it in 7 quarters. The position peaked at $504K in Q3 2018. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2023.

Belpointe Asset Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 6 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2023, an estimated $213.
Belpointe Asset Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2017 and held it in 7 quarters.
Belpointe Asset Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $504K in Q3 2018.
76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.